To this end, a phase 2 trial (COG AALL1521) is evaluating the efficacy and dosage of ruxolitinib combined with chemotherapy in patients with Ph-like ALL with CRLF2 rearrangements and/or additional JAK-STAT pathway abnormalities [15]. Here, CRLF2 is linked to acute lymphoblastic leukemia.